Abcellera Biologics Inc expected to post a loss of 14 cents a share - Earnings Preview
Abcellera Biologics Inc expected to post a loss of 14 cents a share - Earnings Preview
Abcellera Biologics Inc ABCL.OQ ABCL.O is expected to show a fall in quarterly revenue when it reports results on August 5 for the period ending June 30 2026
The Vancouver British Columbia-based company is expected to report a 54.4% decrease in revenue to $7.784 million from $17.08 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Abcellera Biologics Inc is for a loss of 14 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 2.1% in the last three months.
Wall Street's median 12-month price target for Abcellera Biologics Inc is $11.00, about 92.6% above its last closing price of $5.71
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.20 | -0.20 | -0.14 | Beat | 28.5 |
Dec. 31 2026 | -0.18 | -0.17 | -0.03 | Beat | 82.8 |
Sep. 30 2025 | -0.16 | -0.17 | -0.19 | Missed | -12.6 |
Jun. 30 2025 | -0.16 | -0.17 | -0.12 | Beat | 27.7 |
Mar. 31 2025 | -0.14 | -0.14 | -0.15 | Missed | -5.6 |
Dec. 31 2024 | -0.16 | -0.15 | -0.11 | Beat | 28.5 |
Sep. 30 2024 | -0.15 | -0.15 | -0.17 | Missed | -12.1 |
Jun. 30 2024 | -0.14 | -0.14 | -0.13 | Beat | 9.3 |
This summary was machine generated August 3 at 21:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on AbCellera Biologics
See all newsAbCellera Biologics Inc. reports results for the quarter ended September 30 - Earnings Summary
Canada's AbCellera Q3 revenue beats analyst estimates
Factbox: Pharma sector doubles down on AI to slash costs, timelines
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce